Compare SCOR & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SCOR | CGTX |
|---|---|---|
| Founded | 1999 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 112.4M | 110.8M |
| IPO Year | 2007 | 2021 |
| Metric | SCOR | CGTX |
|---|---|---|
| Price | $6.51 | $1.15 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $3.33 |
| AVG Volume (30 Days) | 10.9K | ★ 979.8K |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 127.37 | 62.79 |
| EPS | ★ 4.25 | N/A |
| Revenue | ★ $403,549,000.00 | N/A |
| Revenue This Year | $2.75 | N/A |
| Revenue Next Year | $7.30 | N/A |
| P/E Ratio | $1.65 | ★ N/A |
| Revenue Growth | ★ 1.02 | N/A |
| 52 Week Low | $4.39 | $0.22 |
| 52 Week High | $10.18 | $3.83 |
| Indicator | SCOR | CGTX |
|---|---|---|
| Relative Strength Index (RSI) | 38.39 | 48.73 |
| Support Level | $6.28 | $1.01 |
| Resistance Level | $7.07 | $1.19 |
| Average True Range (ATR) | 0.43 | 0.09 |
| MACD | -0.08 | -0.02 |
| Stochastic Oscillator | 10.10 | 17.02 |
comScore Inc is a information and analytics company that measures advertising, content, and the consumer audiences of each, across media platforms. It create products using a data platform that combines information on digital platforms (connected televisions, mobile devices, tablets and computers), televisions, direct to consumer applications, and movie screens with demographics and other descriptive information. The company has developed proprietary data science that enables measurement of person-level and household-level audiences, removing duplicated viewing across devices and over time. Its segments include Content & Ad Measurement and Research & Insight Solutions of which the Content & Ad Measurement segment derives the majority of the revenue.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system (CNS) and retina. It aims to develop disease-modifying therapies for patients with these disorders. Its product candidate, zervimesine (CT1812), is an orally delivered small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, including beta-amyloid and alpha-synuclein. These protein oligomers have been linked to the progression of degenerative diseases such as Alzheimer's disease (AD) and dementia with Lewy bodies (DLB).